Sanofi
$41.47
−1.17% day
The Nasdaq-listed American depositary shares of Sanofi, the Paris drugmaker. Its earnings lean heavily on Dupixent, an antibody for eczema and asthma, alongside one of the world's largest vaccine businesses.
Oct 23 · $41.47 · −0.5% vs the window’s open
the numbers23
| when | value | change |
|---|---|---|
| Sep 23 | $41.66 | |
| Sep 24 | $40.94 | −1.7% |
| Sep 25 | $41.11 | +0.4% |
| Sep 28 | $41.18 | +0.2% |
| Sep 29 | $40.74 | −1.1% |
| Sep 30 | $41.23 | +1.2% |
| Oct 1 | $40.67 | −1.4% |
| Oct 2 | $39.92 | −1.8% |
| Oct 5 | $39.51 | −1.0% |
| Oct 6 | $39.56 | +0.1% |
| Oct 7 | $40.20 | +1.6% |
| Oct 8 | $40.23 | +0.1% |
| Oct 9 | $40.07 | −0.4% |
| Oct 12 | $39.74 | −0.8% |
| Oct 13low | $39.12 | −1.6% |
| Oct 14 | $39.77 | +1.7% |
| Oct 15 | $40.29 | +1.3% |
| Oct 16 | $40.61 | +0.8% |
| Oct 19 | $39.57 | −2.6% |
| Oct 20 | $41.40 | +4.6% |
| Oct 21 | $40.97 | −1.0% |
| Oct 22high | $41.96 | +2.4% |
| Oct 23latest | $41.47 | −1.2% |
Lately
Sanofi settled an EU antitrust probe in mid-October, the only news about its own business in the fortnight. Nothing reported gives the terms of the settlement or ties it to the share price.